Katherine O'Flaherty1,2, Win Han Oo3, Sophie G Zaloumis2, Julia C Cutts1,4, Kyaw Zayar Aung3, Myat Mon Thein3, Damien R Drew1, Zahra Razook5, Alyssa E Barry1,4,5, Naanki Parischa1, Nyi Nyi Zaw3, Htin Kyaw Thu3, Aung Thi6, Wai Yan Min Htay3, Aung Paing Soe3, Julie A Simpson2, James G Beeson1,4,7, Paul A Agius1,8,9, Freya J I Fowkes10,11,12,13. 1. Burnet Institute for Medical Research and Public Health, Melbourne, Australia. 2. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia. 3. Burnet Institute Myanmar, Yangon, Myanmar. 4. Department of Medicine, University of Melbourne, Melbourne, Australia. 5. School of Medicine, Deakin University, Geelong, Australia. 6. Department of Public Health, Myanmar Ministry of Health, Nay Pyi Taw, Myanmar. 7. Department of Microbiology and Central Clinical School, Monash University, Melbourne, Australia. 8. Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia. 9. Judith Lumley Centre, La Trobe University, Melbourne, Australia. 10. Burnet Institute for Medical Research and Public Health, Melbourne, Australia. freya.fowkes@burnet.edu.au. 11. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia. freya.fowkes@burnet.edu.au. 12. Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia. freya.fowkes@burnet.edu.au. 13. Department of Infectious Diseases, Monash University, Melbourne, Australia. freya.fowkes@burnet.edu.au.
Abstract
BACKGROUND: In the Greater Mekong Subregion (GMS), current malaria surveillance strategies rely on a network of village health volunteers (VHVs) reporting the results of rapid diagnostic tests (RDTs), known to miss many asymptomatic infections. Integration of more sensitive diagnostic molecular and serological measures into the VHV network may improve surveillance of residual malaria transmission in hard-to-reach areas in the region and inform targeted interventions and elimination responses. However, data on residual malaria transmission that would be captured by these measures in the VHV-led testing and treatment surveillance network in the GMS is unknown. METHODS: A total of 114 VHVs were trained to collect dried blood spots from villagers undergoing routine RDTs as part of VHV-led active and passive case detection from April 2015 to June 2016. Samples were subjected to molecular testing (quantitative polymerase chain reaction [qPCR]) to determine Plasmodium falciparum and P. vivax infection and serological testing (against P. falciparum and P. vivax antigens) to determine exposure to P. falciparum and P. vivax. RESULTS: Over 15 months, 114 VHVs performed 32,194 RDTs and collected samples for molecular (n = 13,157) and serological (n = 14,128) testing. The prevalence of molecular-detectable P. falciparum and P. vivax infection was 3.2% compared to the 0.16% prevalence of Plasmodium spp. by RDT, highlighting the large burden of infections undetected by standard surveillance. Peaks in anti-P. falciparum, but not P. vivax, merozoite IgG seroprevalence coincided with seasonal P. falciparum transmission peaks, even in those with no molecularly detectable parasites. At the individual level, antibody seropositivity was associated with reduced odds of contemporaneous P. falciparum (OR for PfCSP 0.51 [95%CI 0.35, 0.76], p = 0.001, PfAMA1 0.70 [95%CI 0.52, 0.93], p = 0.01, and PfMSP2 0.81 [95%CI 0.61, 1.08], p = 0.15), but not P. vivax infection (OR PvAMA1 1.02 [95%CI 0.73, 1.43], p = 0.89) indicating a potential role of immunity in protection against molecular-detectable P. falciparum parasitaemia. CONCLUSIONS: We demonstrated that integration and implementation of sample collection for molecular and serological surveillance into networks of VHV servicing hard-to-reach populations in the GMS is feasible, can capture significant levels of ongoing undetected seasonal malaria transmission and has the potential to supplement current routine RDT testing. Improving malaria surveillance by advancing the integration of molecular and serological techniques, through centralised testing approaches or novel point-of-contact tests, will advance progress, and tracking, towards malaria elimination goals in the GMS.
BACKGROUND: In the Greater Mekong Subregion (GMS), current malaria surveillance strategies rely on a network of village health volunteers (VHVs) reporting the results of rapid diagnostic tests (RDTs), known to miss many asymptomatic infections. Integration of more sensitive diagnostic molecular and serological measures into the VHV network may improve surveillance of residual malaria transmission in hard-to-reach areas in the region and inform targeted interventions and elimination responses. However, data on residual malaria transmission that would be captured by these measures in the VHV-led testing and treatment surveillance network in the GMS is unknown. METHODS: A total of 114 VHVs were trained to collect dried blood spots from villagers undergoing routine RDTs as part of VHV-led active and passive case detection from April 2015 to June 2016. Samples were subjected to molecular testing (quantitative polymerase chain reaction [qPCR]) to determine Plasmodium falciparum and P. vivax infection and serological testing (against P. falciparum and P. vivax antigens) to determine exposure to P. falciparum and P. vivax. RESULTS: Over 15 months, 114 VHVs performed 32,194 RDTs and collected samples for molecular (n = 13,157) and serological (n = 14,128) testing. The prevalence of molecular-detectable P. falciparum and P. vivax infection was 3.2% compared to the 0.16% prevalence of Plasmodium spp. by RDT, highlighting the large burden of infections undetected by standard surveillance. Peaks in anti-P. falciparum, but not P. vivax, merozoite IgG seroprevalence coincided with seasonal P. falciparum transmission peaks, even in those with no molecularly detectable parasites. At the individual level, antibody seropositivity was associated with reduced odds of contemporaneous P. falciparum (OR for PfCSP 0.51 [95%CI 0.35, 0.76], p = 0.001, PfAMA1 0.70 [95%CI 0.52, 0.93], p = 0.01, and PfMSP2 0.81 [95%CI 0.61, 1.08], p = 0.15), but not P. vivax infection (OR PvAMA1 1.02 [95%CI 0.73, 1.43], p = 0.89) indicating a potential role of immunity in protection against molecular-detectable P. falciparum parasitaemia. CONCLUSIONS: We demonstrated that integration and implementation of sample collection for molecular and serological surveillance into networks of VHV servicing hard-to-reach populations in the GMS is feasible, can capture significant levels of ongoing undetected seasonal malaria transmission and has the potential to supplement current routine RDT testing. Improving malaria surveillance by advancing the integration of molecular and serological techniques, through centralised testing approaches or novel point-of-contact tests, will advance progress, and tracking, towards malaria elimination goals in the GMS.
Authors: Rhea J Longley; Michael T White; Eizo Takashima; Jessica Brewster; Masayuki Morita; Matthias Harbers; Thomas Obadia; Leanne J Robinson; Fumie Matsuura; Zoe S J Liu; Connie S N Li-Wai-Suen; Wai-Hong Tham; Julie Healer; Christele Huon; Chetan E Chitnis; Wang Nguitragool; Wuelton Monteiro; Carla Proietti; Denise L Doolan; Andre M Siqueira; Xavier C Ding; Iveth J Gonzalez; James Kazura; Marcus Lacerda; Jetsumon Sattabongkot; Takafumi Tsuboi; Ivo Mueller Journal: Nat Med Date: 2020-05-11 Impact factor: 53.440
Authors: André Lin Ouédraogo; Teun Bousema; Petra Schneider; Sake J de Vlas; Edith Ilboudo-Sanogo; Nadine Cuzin-Ouattara; Issa Nébié; Will Roeffen; Jan Peter Verhave; Adrian J F Luty; Robert Sauerwein Journal: PLoS One Date: 2009-12-22 Impact factor: 3.240
Authors: Chris Cotter; Hugh J W Sturrock; Michelle S Hsiang; Jenny Liu; Allison A Phillips; Jimee Hwang; Cara Smith Gueye; Nancy Fullman; Roly D Gosling; Richard G A Feachem Journal: Lancet Date: 2013-04-15 Impact factor: 79.321
Authors: Petra Schneider; J Teun Bousema; Louis C Gouagna; Silas Otieno; Marga van de Vegte-Bolmer; Sabah A Omar; Robert W Sauerwein Journal: Am J Trop Med Hyg Date: 2007-03 Impact factor: 2.345
Authors: Hannah M Edwards; Sara E Canavati; Chandary Rang; Po Ly; Siv Sovannaroth; Lydie Canier; Nimol Khim; Didier Menard; Ruth A Ashton; Sylvia R Meek; Arantxa Roca-Feltrer Journal: PLoS One Date: 2015-09-09 Impact factor: 3.240
Authors: Lucy C Okell; Teun Bousema; Jamie T Griffin; André Lin Ouédraogo; Azra C Ghani; Chris J Drakeley Journal: Nat Commun Date: 2012 Impact factor: 14.919
Authors: Kevin O Ochwedo; Collince J Omondi; Edwin O Magomere; Julius O Olumeh; Isaiah Debrah; Shirley A Onyango; Pauline W Orondo; Benyl M Ondeto; Harrysone E Atieli; Sidney O Ogolla; John Githure; Antony C A Otieno; Andrew K Githeko; James W Kazura; Wolfgang R Mukabana; Yan Guiyan Journal: Malar J Date: 2021-12-20 Impact factor: 2.979
Authors: Lindsey Wu; Michelle S Hsiang; Lisa M Prach; Leah Schrubbe; Henry Ntuku; Mi-Suk Kang Dufour; Brooke Whittemore; Valerie Scott; Joy Yala; Kathryn W Roberts; Catriona Patterson; Joseph Biggs; Tom Hall; Kevin K A Tetteh; Cara Smith Gueye; Bryan Greenhouse; Adam Bennett; Jennifer L Smith; Stark Katokele; Petrina Uusiku; Davis Mumbengegwi; Roly Gosling; Chris Drakeley; Immo Kleinschmidt Journal: EClinicalMedicine Date: 2022-02-14